When was StimOxyGen founded?

StimOxyGen was founded in 2021 and raised its 1st funding round 4 years after it was founded.

Where is StimOxyGen located?

StimOxyGen is headquartered in Londonderry, United Kingdom. It is registered at VICTORIA HOUSE,GLOUCESTER STREET,BELFAST,NORTHERN IRELAND,BT1 4LS.

Who is the current CEO of StimOxyGen?

Sian Farrell of StimOxyGen. They have also founded 1 company.

Which legal entities is StimOxyGen associated with?

StimOxyGen is associated with STIMOXYGEN LTD.

How many employees does StimOxyGen have?

As of May 31, 2026, the latest employee count at StimOxyGen is 6.

Is StimOxyGen a funded company?

StimOxyGen is a funded company, having raised a total of $3.97M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Mar 11, 2025.

When was the latest funding round of StimOxyGen?

StimOxyGen's latest funding was a $***** Seed round on Jun 25, 2025, with participation from 1 investor. Its primary sector is Oncology. In United Kingdom, the Oncology sector has seen $444M in funding in 2026 to date.

Where does StimOxyGen rank among its competitors?

StimOxyGen ranks 628th amongst 3449 active competitors, of which 1167 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Bio, which secured $40M in May, 2026.

Who are the top competitors of StimOxyGen?

StimOxyGen's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Bio secured the most recent funding round in May, 2026.

StimOxyGen - 2026 Company Profile, Team, Funding, Competitors & Financials

StimOxyGen is a seed company based in Londonderry (United Kingdom), founded in 2021 by Sian Farrell and Tony McHale. It operates as a Developer of therapeutics for cancer treatment. StimOxyGen has raised $3.97M in funding from DSW Ventures. The company has 3449 active competitors, including 1167 funded and 791 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of therapeutics for cancer treatment. It offers oxygen-generating nanoparticles that dissolve in acidic tumor environments to release oxygen and countering tumor hypoxia and improving the efficacy of radiotherapy and immunotherapy. It offers a lead candidate SGEN-33 designed to enhance radiotherapy outcomes by alleviating hypoxic resistance.

Website: stimoxygen.com
Social
Registered Address: VICTORIA HOUSE,GLOUCESTER STREET,BELFAST,NORTHERN IRELAND,BT1 4LS

Key Metrics

Founded Year

2021

Location

Londonderry, United Kingdom

Stage

Seed

Total Funding

$3.97M in 3 rounds

Latest Funding Round

Seed, Jun 25, 2025, $*****

Investors

DSW Ventures & 4 more

Ranked

628^th among 3449 active competitors

Employee Count

6 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3252 more

View StimOxyGen's full profile

StimOxyGen is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
STIMOXYGEN LTD CIN: NI677236 , United Kingdom, Active	Mar 08, 2021	-	2 (As on Mar 31, 2025)

StimOxyGen has raised a total funding of $3.97M over 3 rounds. Its first funding round was on Mar 11, 2025. Its latest funding round was a Seed round on Jun 25, 2025 for $*****. 1 investor participated in its latest round. StimOxyGen has 5 institutional investors.

Here is the list of recent funding rounds of StimOxyGen:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 25, 2025	2379131	Seed	1468521	2272599	6363882	8889391
Mar 11, 2025	6536833	Grant (prize money)	5103883	4159895	6270143	Ukri
Mar 11, 2025	9238010	Seed	8119039	4555050	DSW Ventures	Qubis & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of StimOxyGen's funding rounds and investors

The founders of StimOxyGen are Sian Farrell and Tony McHale. Sian Farrell is the CEO of StimOxyGen.

Here are the details of StimOxyGen's key team members:

Sian Farrell: Co-Founder & CEO of StimOxyGen. They serve on the board of 1 company.
Contact Info: 1 email address
Tony McHale: Co-Founder of StimOxyGen.

StimOxyGen's Board of Directors

StimOxyGen's board has 5 active members. Sian Farrell is part of team and Prof Anthony Mchale, Fergus Begley, Samuel Rothstein and Dr Leslie James Russell are independent board members.

Here is the list of StimOxyGen's board of directors:

Name	Type	Representing	Status	Duration
Sian Farrell	Team	-	Current	5y 3m
Prof Anthony Mchale	Independent board member	-	Current	5y 3m
yfm{nnm	Independent board member	-	Current	7y 5m
bdy{emd	Independent board member	-	Current	1y 5m
fymdqjn	Independent board member	-	Current	6y 9m

View details of StimOxyGen's Founder profiles and Board Members

StimOxyGen's employee count trend

StimOxyGen has 6 employees as of May 26. Here is StimOxyGen's employee count trend over the years:

Uncover StimOxyGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of StimOxyGen include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of StimOxyGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
628th	StimOxyGen 2021, Londonderry (United Kingdom), Seed	Developer of therapeutics for cancer treatment	$3.97M	Invest Northern Ireland, Qubis & 3 others	49/100